Narrow search
Showing 1 - 10 of 24,637
Cover Image
Assessing consumer gains from a drug price control policy in the United States
Santerre, Rexford E.; Vernon, John A. - In: Southern economic journal 73 (2006) 1, pp. 233-245
Persistent link: https://www.econbiz.de/10003353924
Cover Image
Assessing consumer gains from a drug price control policy in the US
Santerre, Rexford E.; Vernon, John A. - 2005
Persistent link: https://www.econbiz.de/10002619621
Cover Image
Assessing Consumer Gains from a Drug Price Control Policy in the U.S
Santerre, Rexford E. - 2007
pharmaceuticals in the U.S. The estimated demand curve is then used to simulate the value of consumer surplus gains from a drug price …This paper uses national data for the period 1960 to 2000 to estimate an aggregate private consumer demand for …. Recent research on the value of pharmaceuticals suggests that the social benefits of a new drug may be far greater than this …
Persistent link: https://www.econbiz.de/10012778705
Cover Image
Tiered co-payments, pricing, and demand in reference price markets for pharmaceuticals
Herr, Annika; Suppliet, Moritz - In: Journal of health economics 56 (2017), pp. 19-29
Persistent link: https://www.econbiz.de/10011798902
Cover Image
Price controls for medical innovations in a life cycle perspective
Sorek, Gilad - In: Health economics 23 (2014) 1, pp. 108-116
Persistent link: https://www.econbiz.de/10010257208
Cover Image
Deregulation and access to medicines : the Peruvian experience
Costa-Font, Joan - In: Journal of international development : the journal of … 28 (2016) 6, pp. 997-1005
Persistent link: https://www.econbiz.de/10011552915
Cover Image
Pricing the pharmaceuticals when the ability to pay differs
Kanniainen, Vesa; Laine, Juha; Linnosmaa, Ismo - In: Journal of the Finnish Economic Association : JFEA 2 (2021) 1, pp. 25-48
A non-trivial fraction of people cannot afford to buy pharmaceutical products at unregulated market prices. This paper analyses the public insurance of a patent-protected pharmaceutical product in terms of price controls and socially optimal third-degree price discrimination. First, the paper...
Persistent link: https://www.econbiz.de/10013286496
Cover Image
Pricing the pharmaceuticals when the ability to pay differs : taking vertical equity seriously
Kanniainen, Vesa; Laine, Juha; Linnosmaa, Ismo - 2019
A non-trivial fraction of people cannot afford to buy pharmaceutical products at unregulated market prices. Therefore, the paper analyzes the public insurance of the pharmaceutical products in terms of price controls and the socially optimal third-degree price discrimination. It characterizes...
Persistent link: https://www.econbiz.de/10012157261
Cover Image
Pharmaceutical spending and early-stage innovation in EU countries
Kourouklis, Dimitrios; Gandjour, Afschin - In: Industry and innovation 29 (2022) 10, pp. 1141-1170
Persistent link: https://www.econbiz.de/10013493053
Cover Image
The effects of drug market regulation on pharmaceutical prices in Europe : overview and evidence from the market of ACE inhibitors
Schulenburg, Fritz von der; Vandoros, Sotiris; Kanavos, … - In: Health economics review 1 (2011) 18, pp. 1-8
in reducing pharmaceuticals prices. Results are not as strong for demand side measures. Profit controls and the use of …
Persistent link: https://www.econbiz.de/10009503923